Rabbit IgG polyclonal antibody for Mothers against decapentaplegic homolog 1 (SMAD1) detection. Tested with WB in Human, Mouse, Rat.
Immunogen
A synthetic peptide corresponding to a sequence at the C-terminal of human Smad 1,2,3,5, identical to the related mouse and rat sequences.< br/>Immunogen was affinity purified.
At -20 °C for one year. After reconstitution, at 4 °C for one month. It can also be aliquotted and stored frozen at -20 °C for a longer time.
Zhu, Kavsak, Abdollah, Wrana, Thomsen: "A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation." in: Nature, Vol. 400, Issue 6745, pp. 687-93, (1999) (PubMed).
Target
SMAD1
(SMAD, Mothers Against DPP Homolog 1 (SMAD1))
Alternative Name
Mothers against decapentaplegic homolog 1(MAD homolog 1/Mothers against DPP homolog 1) (SMAD1 Products)
Background
SMADs are proteins that modulate the activity of transforming growth factor beta ligands. The SMADs, often in complex with other SMADs/CoSMAD, act as transcription factors that regulate the expression of certain genes. Zhu, H et al concluded that targeted ubiquitination of SMADs may serve to control both embryonic development and a wide variety of cellular responses to TGF-beta signals. R-Smads or receptor regulated Smads are a class of proteins that include SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8. In response to signals by the TGF-beta superfamily of ligands these proteins associate with receptor kinases and are phosphorylated at an SSXS motif at their extreme C-terminus. These proteins then typically bind to the common mediator Smad or co-SMAD SMAD4.